keyword
MENU ▼
Read by QxMD icon Read
search

Symptom management prostate cancer

keyword
https://www.readbyqxmd.com/read/27914560/diagnosis-and-treatment-of-testosterone-deficiency-recommendations-from-the-fourth-international-consultation-for-sexual-medicine-icsm%C3%A2-2015
#1
Mohit Khera, Ganesh Adaikan, Jacques Buvat, Serge Carrier, Amr El-Meliegy, Kostas Hatzimouratidis, Andrew McCullough, Abraham Morgentaler, Luiz Otavio Torres, Andrea Salonia
INTRODUCTION: Testosterone deficiency (TD), also known as hypogonadism, is a condition affecting a substantial proportion of men as they age. The diagnosis and management of TD can be challenging and clinicians should be aware of the current literature on this condition. AIM: To review the available literature concerning the diagnosis and management of TD and to provide clinically relevant recommendations from the Fourth International Consultation for Sexual Medicine (ICSM) meeting...
December 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27878318/-corticosteroids-in-the-management-of-advanced-prostate-cancer
#2
H Kübler
Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone...
November 22, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27844130/-second-neoplasms-after-percutaneous-radiotherapy
#3
F Haidl, D Pfister, R Semrau, A Heidenreich
Radiation therapy represents an alternative treatment to radical prostatectomy in the management of clinically localized prostate cancer. Radiation-induced second neoplasms are defined by a latency period of at least 5 years, location within the field of radiation therapy, and a histology which differs from the primary tumor. Based on the data in the literature, there is a consistently increased risk of bladder cancer (HR: 1.67, 95% CI 1.55-1.80), rectal cancer (HR: 1.79, 95% CI 1.34-2.38), and colorectal cancer (HR: 1...
November 14, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27836000/unusual-side-effect-from-a-luteinizing-hormone-releasing-hormone-agonist-leuprorelin-in-the-treatment-of-prostate-cancer-a-case-report
#4
John I-Chiang Chang, Joseph Bucci
BACKGROUND: The treatment options for high-risk prostate cancer are either radical prostatectomy or radiotherapy/brachytherapy depending on the patients' prognosis. In older men with multiple comorbidities, radiotherapy with androgen deprivation therapy is an attractive option. Common side effects of androgen deprivation therapy include hot flushes, tiredness, increased risk of fractures, increased risk of metabolic disorders, coronary heart disease, and psychological effects. This case highlights the potential side effect of lipodystrophy secondary to leuprolide acetate injections...
November 11, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27768127/fatigue-self-management-behaviors-in-patients-with-advanced-cancer-a-prospective-longitudinal-survey
#5
Raymond Chan, Patsy Yates, Alexandra L McCarthy
PURPOSE/OBJECTIVES: To explore the fatigue self-management behaviors and factors associated with effectiveness of these behaviors in patients with advanced cancer.
. DESIGN: Prospective longitudinal interviewer-administered survey.
. SETTING: Royal Brisbane and Women's Hospital in Queensland, Australia.
. SAMPLE: 152 outpatients with metastatic breast, lung, colorectal, and prostate cancer experiencing fatigue were recruited...
November 1, 2016: Oncology Nursing Forum
https://www.readbyqxmd.com/read/27754846/advances-in-the-management-of-castration-resistant-prostate-cancer
#6
Chad R Ritch, Michael S Cookson
Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab)...
October 17, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27697869/improving-the-well-being-of-men-by-evaluating-and-addressing-the-gastrointestinal-late-effects-eagle-of-radical-treatment-for-prostate-cancer-study-protocol-for-a-mixed-method-implementation-project
#7
Sophia Taylor, Weyinmi Demeyin, Ann Muls, Catherine Ferguson, Damian J J Farnell, David Cohen, Jervoise Andreyev, John Green, Lesley Smith, Sam Ahmedzai, Sara Pickett, Annmarie Nelson, John Staffurth
INTRODUCTION: Radiotherapy treatment for prostate cancer can cause bowel problems, which may lead to severe difficulties for cancer survivors including limiting travel, work or socialising. These symptoms can appear at any time following radiotherapy. This study focuses on the early identification and protocol-based management of effects known to cause long-term, or even permanent, changes to the well-being of prostate cancer survivors. The rationale of this study is to improve the care offered to men and their families following pelvic radiotherapy for prostate cancer...
October 3, 2016: BMJ Open
https://www.readbyqxmd.com/read/27581270/endocrine-society-of-australia-position-statement-on-male-hypogonadism-part-2-treatment-and-therapeutic-considerations
#8
Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn Ga Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac, Henry G Burger
INTRODUCTION: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. MAIN RECOMMENDATIONS: Key points and recommendations are:Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment...
September 5, 2016: Medical Journal of Australia
https://www.readbyqxmd.com/read/27562520/-red-blood-transfusion-in-palliative-care-situation
#9
C Velter, V Montheil, J Alexandre, P Vinant, F Goldwasser
Anemia is frequent in oncology. We debate the decision-making process of erythrocyte transfusion in palliative care situation from a case report. A patient with a prostatic metastatic cancer was in palliative situation with asthenia and coronary symptom. We analyze, in this particular case that does not describe reality of normal practice, the decision-making process of erythrocyte transfusion. These transfusions were based, in this case, on the evaluation of oncology prognosis, the short-term vital threats, life project and clinical safety of the transfusion...
September 2016: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
https://www.readbyqxmd.com/read/27544558/holmium-laser-for-the-surgical-treatment-of-benign-prostatic-hyperplasia
#10
Portia Thurmond, Sanchita Bose, Lori B Lerner
INTRODUCTION: Holmium laser ablation of the prostate (HoLAP) is a surgical approach for treatment of benign prostatic hyperplasia (BPH). Limited evidence suggests laser ablation/vaporization is inferior to enucleation with respect to reoperation rates. Our objective was to determine if properly performed laser ablation results in outcomes similar to enucleation. MATERIALS AND METHODS: A total of 198 patients with moderate to severe lower urinary tract symptoms and/or acute urinary retention had holmium laser enucleation of the prostate (HoLEP) or HoLAP between 2008 and 2014...
August 2016: Canadian Journal of Urology
https://www.readbyqxmd.com/read/27500085/benign-or-malignant-two-case-reports-of-gigantic-prostatic-cyst
#11
Jiang Yu, Xizhi Wang, Feiye Luo, Bo Wang, Yi Wang
A 60-year-old male with a huge prostate cyst presented with obstruction symptom of urethra and intestinal tract. Complete excision of the cystic prostate failed as a result of the strong adherence and twice operations history, but we confirmed prostate adenocarcinoma and relieved his obstruction symptom. Case 2 was a 77-year-old male with an 8 cm cyst of which biopsy showed prostate cancer in local hospital. He was admitted 18 months later because of intestinal obstruction. Radical resection had a satisfied result of obstruction symptom and PSA...
September 2016: Urology Case Reports
https://www.readbyqxmd.com/read/27485119/quality-of-life-effects-of-androgen-deprivation-therapy-in-a-prostate-cancer-cohort-in-new-zealand-can-we-minimize-effects-using-a-stratification-based-on-the-aldo-keto-reductase-family-1-member-c3-rs12529-gene-polymorphism
#12
Nishi Karunasinghe, Yifei Zhu, Dug Yeo Han, Katja Lange, Shuotun Zhu, Alice Wang, Stephanie Ellett, Jonathan Masters, Megan Goudie, Justin Keogh, Benji Benjamin, Michael Holmes, Lynnette R Ferguson
BACKGROUND: Androgen deprivation therapy (ADT) is an effective palliation treatment in men with advanced prostate cancer (PC). However, ADT has well documented side effects that could alter the patient's health-related quality of life (HRQoL). The current study aims to test whether a genetic stratification could provide better knowledge for optimising ADT options to minimize HRQoL effects. METHODS: A cohort of 206 PC survivors (75 treated with and 131 without ADT) was recruited with written consent to collect patient characteristics, clinical data and HRQoL data related to PC management...
2016: BMC Urology
https://www.readbyqxmd.com/read/27476838/histopathological-examination-of-spine-tumors-after-treatment-with-radiosurgery
#13
Nathan T Zwagerman, Michael M McDowell, Ronald L Hamilton, Edward A Monaco, John C Flickinger, Peter C Gerszten
OBJECTIVE Increased survival time after diagnosis of neoplastic disease has resulted in a gradual increase in spine tumor incidence. Radiosurgery is frequently a viable alternative to operative management in a population with severe medical comorbidities. The authors sought to assess the histopathological consequences of radiosurgery in the subset of patients progressing to operative intervention. METHODS Eighteen patients who underwent radiosurgery for spine tumors between 2008 and 2014 subsequently progressed to surgical treatment...
August 2016: Neurosurgical Focus
https://www.readbyqxmd.com/read/27390688/health-technology-assessment-of-image-guided-radiotherapy-igrt-a-systematic-review-of-current-evidence
#14
Jalal Arabloo, Pejman Hamouzadeh, Seyedeh Maryam Mousavinezhad, Mohammadreza Mobinizadeh, Alireza Olyaeemanesh, Morvarid Pooyandjoo
BACKGROUND: Image-guided radiotherapy used multiple imaging during the radiation therapy course to improve the precision and accuracy of health care provider's treatment. OBJECTIVES: This study aims to assess the safety, effectiveness and economic aspects of image-guided radiation therapy for decision-making about this technology in Iran. METHODS: In this study, the most important medical databases such as PubMed and Cochrane Library were searched until November 2014...
2016: Medical Journal of the Islamic Republic of Iran
https://www.readbyqxmd.com/read/27390687/degarelix-for-the-treatment-of-advanced-prostate-cancer-compared-with-gnrh-agonists-a-systematic-review-and-meta-analysis
#15
Seyed Alireza Hosseini, Fatemeh Rajabi, Ali Akbari Sari, Mohsen Ayati, Saeed Heidari, Fawzieh Ghamary
BACKGROUND: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. METHODS: MEDLINE, Web of Science and the Cochrane library were searched to identify all of the published Randomized Controlled Trials (RCTs) that used degarelix versus gonadotropin-releasing hormone agonists with or without anti-androgen therapy for the treatment of prostate cancer...
2016: Medical Journal of the Islamic Republic of Iran
https://www.readbyqxmd.com/read/27385897/metastasis-in-urothelial-carcinoma-mimicking-prostate-cancer-metastasis-in-ga-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-a-case-of-synchronous-malignancy
#16
Manoj Gupta, Partha Sarathi Choudhury, Gurudutt Gupta, Jatin Gandhi
Prostate cancer is the second most common cancer in man. It commonly presents with urinary symptoms, bone pain, or diagnosed with elevated prostate-specific antigen.(PSA) levels. Correct staging and early diagnosis of recurrence by a precise imaging tool are the keys for optimum management. Molecular imaging of prostate cancer with Ga-68 prostate-specific membrane antigen.(PSMA), positron emission tomography-computed tomography.(PET-CT) has recently received significant attention and frequently used with a signature to prostate cancer-specific remark...
July 2016: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/27342944/stereotactic-body-re-irradiation-therapy-for-locally-recurrent-prostate-cancer-after-external-beam-radiation-therapy-initial-report
#17
G Janoray, A Reynaud-Bougnoux, A Ruffier-Loubière, G Bernadou, Y Pointreau, G Calais
PURPOSE: Management of prostate cancer relapses after external-beam radiation therapy is still undefined. Re-irradiation schedules have been explored in different tumour sites. In this report, we present our preliminary experience of re-irradiation using stereotactic body radiotherapy for localized prostate cancer failure. MATERIAL AND METHODS: Between March 2011 and October 2014, robotic stereotactic body radiation therapy was administered to patients previously treated with external-beam radiation therapy to a median dose of 71...
June 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/27337973/phytotherapeutic-agents-for-benign-prostatic-hyperplasia-an-overview
#18
Neelima Dhingra Passi
Benign prostatic hyperplasia (BPH) the most common condition in aging men is the non malignant enlargement of the prostate gland with increase in numbers of both epithelial and stromal cells within the periurethal transition zone of the prostate. Sources of symptoms in patient with BPH appear to be both static and dynamic component. Management of BPH has undergone a rapid evolution over the past decade to aid men with lower urinary tract symptoms attributed to bladder outlet obstruction. Treatment of clinical BPH aims to improve symptoms, prevent urinary tract infections, avoid renal insult, relief obstruction and improve bladder emptying...
June 20, 2016: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/27337754/managing-lower-urinary-tract-symptoms-in-men
#19
REVIEW
Kenneth R MacKenzie, Jonathan J Aning
Male lower urinary tract symptoms (LUTS) are common and increase in prevalence with age. Up to 90% of men aged 50 to 80 may suffer from troublesome LUTS. Men may attend expressing direct concern about micturition, describing one or more LUTS and the related impact on their quality of life. Frequently men may present for other medical or urological reasons such as concern regarding their risk of having prostate cancer or erectile dysfunction but on taking a history bothersome LUTS are identified. Men may present late in the community with urinary retention: the inability to pass urine...
April 2016: Practitioner
https://www.readbyqxmd.com/read/27294289/men-s-experience-of-a-guided-self-help-intervention-for-hot-flushes-associated-with-prostate-cancer-treatment
#20
E A Grunfeld, M S Hunter, O Yousaf
Up to 80% of men who receive androgen deprivation therapy report hot flushes and for many these are associated with reduced quality of life. However it is recognised that there are a number of barriers to men's engagement with support to manage symptoms and improve quality of life. This qualitative study was embedded within a larger randomised controlled trial (MANCAN) of a guided self-help cognitive behavioural intervention to manage hot flushes resulting among men receiving androgen deprivation therapy. The study aimed to explore the engagement and experiences with the guided self-help intervention...
June 13, 2016: Psychology, Health & Medicine
keyword
keyword
3371
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"